abt-418 abt-418 abt-418 is a drug developed by abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both alzheimer's disease and adhd. it acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-ht3, and α2β2 nicotinic acetylcholine receptors but not α3β4 receptors abt-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether abt-418 itself will proceed to clinical development or if another similar drug will be used instead. abt-418identifiers iupac name 3-methyl-5--1,2-oxazole cas number147402-53-7 npubchem cid119380chemspider106627 yuniib9i6mzl7bwchemblchembl274525 ycomptox dashboard (epa)dtxsid10163711 chemical and physical dataformulac9h14n2omolar mass166.22 g·mol−13d model (jsmol)interactive image smiles cc1=noc(=c1)2cccn2c inchi inchi=1s/c9h14n2o/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8h,3-5h2,1-2h3/t8-/m0/s1 ykey:illgyrjayaaaew-qmmmgpobsa-n y ny (what is this?) (verify)